News Search:
Davis Polk Advises Shire on Its Acquisition of FerroKin BioSciences
Davis Polk is advising Shire plc on its acquisition of FerroKin BioSciences, Inc. for an upfront payment of $100 million plus potential post-closing milestone payments of up to $225 million. The closing of the acquisition is subject to customary conditions.

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. FerroKin BioSciences is a clinical stage biotechnology company dedicated to improving the management of patients with iron overload.

The Davis Polk corporate team includes partner William J. Chudd and associates Alexander N. Macleod and Xiaoxi Lin. Partner Kyoko Takahashi Lin and associates Andrew Blau and Jeffrey Brenner (not yet admitted) are providing employee benefits advice. Partner Frank J. Azzopardi and associate David R. Bauer are providing intellectual property advice. The tax team includes partner Michael Mollerus and associate Kerry S. Price. All members of the Davis Polk deal team are based in the New York office.